Table 2.
Characteristics of ongoing clinical trials evaluated from cancer clinical trial questionnaire results
| Classifying clinical trial | No. of clinical trials (%) | |
|---|---|---|
| Researchers behavior | Interventional study | 663 (76.6) |
| Observational study | 203 (23.4) | |
| Participating institute | Single center study | 138 (15.8) |
| Multicenter study | 738 (84.2) | |
| Purpose | Chemotherapeutic study | 694 (79.2) |
| Cancer prevention study | 4 (0.5) | |
| Cancer diagnostic study | 17 (1.9) | |
| Palliative study | 64 (7.3) | |
| Cancer screening study | 5 (0.6) | |
| Basic study | 36 (4.1) | |
| Others | 56 (6.4) | |
| Phase | Phase 1 | 37 (4.3) |
| Phase 2 | 363 (42.0) | |
| Phase 3 | 253 (29.2) | |
| Phase 4 or PMS | 150 (17.3) | |
| Translational research | 62 (7.2) | |
| Study method | Single group study | 488 (61.5) |
| Parallel study | 256 (32.3) | |
| Cross-over study | 30 (3.8) | |
| Factorial study | 19 (2.4) | |
| Masking | Open study | 540 (72.7) |
| Single blind study | 65 (8.7) | |
| Double blind study | 138 (18.6) | |
| Allocation | Single arm study | 409 (48.5) |
| Randomized controlled trial study | 327 (38.7) | |
| Non-randomized trial study | 108 (12.8) | |
| Target number | < 50 persons | 436 (50.6) |
| 50-100 persons | 161 (18.7) | |
| > 100 persons | 265 (30.7) | |
| Direction and timing | Prospective study | 685 (83.4) |
| Retrospective study | 94 (11.4) | |
| Cross-sectional study | 26 (3.2) | |
| Others | 16 (1.9) | |
| Characteristics of intervention | Drug | 614(81.3) |
| Equipment | 6 (0.8) | |
| Biologic agent and vaccine | 13 (1.7) | |
| Surgery and management | 10 (1.3) | |
| Radiotherapy | 17 (2.3) | |
| Genetic test | 44 (5.8) | |
| Supportive care and adjuvant | 15 (2.0) | |
| Others | 36 (4.8) |
PMS, postmarketing survey.